Similar articles for PMID: 31628220

Year	Number of Results
2002	1
2003	1
2005	2
2006	1
2007	1
2008	1
2009	1
2010	2
2011	1
2012	1
2013	6
2014	6
2015	8
2016	16
2017	18
2018	20
2019	24
2020	31
2021	28
2022	21
2023	12
2024	0

1

Early ¹⁸F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab.

Chen A, Mokrane FZ, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella JM, Vercellino L, Casasnovas O, Chauchet A, Delmer A, Nicolas-Virelizier E, Ghesquières H, Moles-Moreau MP, Schmitt A, Dulery R, Bouabdallah K, Borel C, Touati M, Deau-Fischer B, Peyrade F, Seban RD, Manson G, Armand P, Houot R, Dercle L. Chen A, et al. J Nucl Med. 2020 May;61(5):649-654. doi: 10.2967/jnumed.119.232827. Epub 2019 Oct 18. J Nucl Med. 2020. PMID: 31628220 Free article.

2

Performance of CT Compared with ¹⁸F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma.

Mokrane FZ, Chen A, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella JM, Vercellino L, Casasnovas O, Chauchet A, Delmer A, Nicolas-Virelizier E, Ghesquières H, Moles-Moreau MP, Schmitt A, Duléry R, Bouabdallah K, Borel C, Touati M, Deau-Fischer B, Peyrade F, Seban RD, Manson G, Houot R, Dercle L. Mokrane FZ, et al. Radiology. 2020 Jun;295(3):651-661. doi: 10.1148/radiol.2020192056. Epub 2020 Apr 14. Radiology. 2020. PMID: 32286191

3

¹⁸F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.

Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S, Danu A, Edeline V, Marabelle A, Ribrag V, Michot JM. Dercle L, et al. J Nucl Med. 2018 Jan;59(1):15-24. doi: 10.2967/jnumed.117.193011. Epub 2017 Jun 8. J Nucl Med. 2018. PMID: 28596157 Free article.

4

Early evaluation of tumor response to ⁹⁰Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?

Kitajima K, Okada M, Kashiwagi T, Yoshihara K, Tokugawa T, Sawada A, Yoshihara S, Fujimori Y, Yamakado K. Kitajima K, et al. Eur Radiol. 2019 Jul;29(7):3935-3944. doi: 10.1007/s00330-019-06134-7. Epub 2019 Mar 21. Eur Radiol. 2019. PMID: 30899979

5

Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.

Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1932-1943. doi: 10.1007/s00259-020-05137-7. Epub 2020 Dec 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33336264 Free PMC article.

6

2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.

Salvatore B, Fonti R, De Renzo A, Pellegrino S, Ferrara IL, Mainolfi CG, Marano L, Selleri C, Pane F, Del Vecchio S, Pace L. Salvatore B, et al. Q J Nucl Med Mol Imaging. 2020 Jun;64(2):219-225. doi: 10.23736/S1824-4785.18.03043-1. Epub 2018 Apr 24. Q J Nucl Med Mol Imaging. 2020. PMID: 29697219

7

Prognostic role of pretreatment ¹⁸F-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study.

Yang T, Liu S, Zuo R, Liang H, Xu L, Wang Z, Chen X, Pang H. Yang T, et al. BMC Med Imaging. 2023 Jan 21;23(1):12. doi: 10.1186/s12880-023-00967-x. BMC Med Imaging. 2023. PMID: 36681824 Free PMC article.

8

Intratumor Heterogeneity Assessed by ¹⁸F-FDG PET/CT Predicts Treatment Response and Survival Outcomes in Patients with Hodgkin Lymphoma.

Lue KH, Wu YF, Liu SH, Hsieh TC, Chuang KS, Lin HH, Chen YH. Lue KH, et al. Acad Radiol. 2020 Aug;27(8):e183-e192. doi: 10.1016/j.acra.2019.10.015. Epub 2019 Nov 21. Acad Radiol. 2020. PMID: 31761665

9

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.

Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, Hunter MO, Akhurst T, Hofman MS, Lau PKH, Kee D, Au-Yeung G, Sandhu S, Hicks RJ. Iravani A, et al. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786. doi: 10.1007/s00259-020-04815-w. Epub 2020 Apr 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 32338306

10

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C. Kahraman D, et al. Leuk Lymphoma. 2014 Apr;55(4):811-6. doi: 10.3109/10428194.2013.819575. Epub 2013 Jul 29. Leuk Lymphoma. 2014. PMID: 23805904

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

161 results

Results by year